MME and heart failure: Increasing the level of peptides degraded by enkephalinase (e.g., natriuretic peptide) by LBO657 and inhibiting angiotensin II I by valsartan produce cardiovascular and renal effects in patients with heart failure (Rivas García and Álvarez-García, 2024).